Open access
Open access
Powered by Google Translator Translator

RCT | Two-year effects of Semaglutide in adults with overweight or obesity.

18 Oct, 2022 | 12:53h | UTC

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial – Nature Medicine

Commentary: STEP 5: Sustained semaglutide treatment maintains weight loss – medwire News

Related:

RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity

RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes

RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

RCT: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.